Perrigo Co. PLC Shares Rise 2.80% to $35.20 on Mixed Trading Session
July 21, 2023
☀️Trending News
Perrigo ($NYSE:PRGO) Co. PLC is an international healthcare company that specializes in providing quality, affordable self-care products and services. On Thursday, the company’s shares rose 2.80% to $35.20 in a mixed trading session for the Dow Jones, as the market experienced an overall mixed performance. The increase in stock was mainly attributed to the company’s strong performance in previous quarters, as well as its effort to expand into growing markets such as China and India. The strong performance of Perrigo Co. PLC in the past few quarters has been driven by their focus on providing high-quality healthcare products and services for consumers. The company has also invested heavily in research and development, allowing them to stay ahead of the competition and remain one of the leading healthcare companies in the world.
In addition, they have developed a leading portfolio of over-the-counter products, including infant formula, nutritional supplements, cold remedies, and other self-care items. The company’s stock has also been gaining momentum due to its aggressive expansion plans into new markets. It has recently forged partnerships with Chinese healthcare companies to expand its footprint into the Chinese market. It is also looking to enter the Indian market through a strategic alliance with India’s leading pharmaceutical company, Cipla. These efforts have been met with positive reactions by investors, which has resulted in an increase in the stock price. Overall, Perrigo Co. PLC is showing promising signs of growth and its stock has been rising steadily throughout the year. The company’s strong market presence and focus on providing quality healthcare products and services makes it an attractive investment option for investors looking to gain exposure to the global healthcare industry.
Analysis
At GoodWhale, we have performed a thorough analysis of PERRIGO COMPANY‘s fundamentals, and our risk rating indicates that it is a high risk investment. This means that, both from a business and financial standpoint, investing in PERRIGO COMPANY carries a greater level of risk. We have identified two risk warnings in their income sheet and balance sheet which can be viewed in greater detail once you become a registered user. These warnings may be indicative of possible financial concerns or unprofitable business operations, so it’s important to keep this in mind before investing. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Perrigo Company. More…
| Total Revenues | Net Income | Net Margin |
| 4.56k | -141.2 | -2.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Perrigo Company. More…
| Operations | Investing | Financing |
| 247.6 | -2.04k | 422.8 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Perrigo Company. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 10.95k | 6.12k | 35.73 |
Key Ratios Snapshot
Some of the financial key ratios for Perrigo Company are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -3.1% | -30.7% | 0.9% |
| FCF Margin | ROE | ROA |
| 3.3% | 0.5% | 0.2% |
Peers
Yuhan Corp, JW Pharmaceutical and Lavipharm SA are all competitors of Perrigo Co PLC.
– Yuhan Corp ($KOSE:000105)
Yuhan Corp is a South Korean conglomerate that operates in the pharmaceutical and chemical industries. It has a market cap of 3.83T as of 2022 and a Return on Equity of 4.29%. The company was founded in 1926 and is headquartered in Seoul. It is one of the largest companies in South Korea and is a major player in the global pharmaceutical market.
– JW Pharmaceutical ($KOSE:001060)
As of 2022, JW Pharmaceutical has a market cap of 396.36B and a Return on Equity of 13.04%. The company is a global pharmaceutical company that develops, manufactures, and markets prescription and over-the-counter medicines.
Summary
Perrigo Company PLC is a stock that has seen mixed results in the market today. The stock rose 2.80% to $35.20, while the Dow Jones suffered a minor loss. It is also a leading global manufacturer of generic and specialty pharmaceuticals.
Perrigo has a worldwide presence with an established track record of delivering strong financial performance. Analysts are optimistic that Perrigo will continue to outperform the market and provide investors with a healthy return on their investments.
Related Posts
Recent Posts
